Halozyme Therapeutics HALO Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's gross margin?
- Halozyme Therapeutics (HALO) reported gross margin of 82.8% in Q1 2026.
- How has Halozyme Therapeutics's gross margin changed year-over-year?
- Halozyme Therapeutics's gross margin decreased by 0.8% year-over-year, from 83.4% to 82.8%.
- What is the long-term trend for Halozyme Therapeutics's gross margin?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's gross margin has grown at a -0.0% compound annual growth rate (CAGR), from 83.8% to 83.6%.
- What does gross margin mean?
- How much of every sales dollar is left after the direct cost of what was sold.
- How do you interpret gross margin?
- Higher and stable gross margins indicate pricing power and a durable cost structure. A declining trend signals input-cost pressure, pricing competition, or a shift toward lower-margin products.
- How does gross margin compare across companies?
- Highly comparable within an industry, less so across industries — software runs 70%+ while distributors run in single digits. Track the trend more than the absolute level across sectors.